Stephens Lowers Medifast (NYSE:MED) Price Target to $12.00

Medifast (NYSE:MED) had its target price decreased by stock analysts at Stephens from $15.00 to $12.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the specialty retailer’s stock. Stephens’ target price would indicate a potential upside of 12.06% from the stock’s current price.

Other research analysts have also issued research reports about the company. Wall Street Zen raised Medifast from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Weiss Ratings reiterated a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Medifast has an average rating of “Reduce” and an average price target of $12.00.

Medifast Trading Down 0.8%

Medifast stock opened at $10.71 on Thursday. The stock has a 50-day moving average price of $11.33 and a 200 day moving average price of $12.31. Medifast has a 52 week low of $10.10 and a 52 week high of $15.95. The stock has a market cap of $117.69 million, a PE ratio of -6.26 and a beta of 0.53.

Medifast (NYSE:MED) last released its quarterly earnings results on Tuesday, February 17th. The specialty retailer reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.21. The company had revenue of $75.10 million for the quarter, compared to analysts’ expectations of $71.40 million. Medifast had a negative net margin of 4.84% and a negative return on equity of 4.19%. Medifast has set its FY 2026 guidance at -2.750–1.55 EPS and its Q1 2026 guidance at -0.700–0.15 EPS. On average, equities analysts predict that Medifast will post 0.51 EPS for the current year.

Hedge Funds Weigh In On Medifast

Hedge funds and other institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. increased its position in Medifast by 261.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,001 shares of the specialty retailer’s stock worth $28,000 after purchasing an additional 1,448 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Medifast by 370.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,144 shares of the specialty retailer’s stock valued at $30,000 after acquiring an additional 1,688 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Medifast by 103.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after purchasing an additional 1,187 shares during the period. Quantbot Technologies LP acquired a new stake in Medifast in the 3rd quarter valued at $37,000. Finally, Intesa Sanpaolo Wealth Management purchased a new position in Medifast in the fourth quarter valued at about $47,000. 95.51% of the stock is owned by institutional investors and hedge funds.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.